A Randomized, Open-Label, Phase II Study of Canakinumab or Pembrolizumab As Monotherapy or in Combination as Neoadjuvant Therapy in Subjects with Resectable Non-Small Cell Lung Cancer CANOPY-N

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03968419

Study #:
STUDY00145288

Start Date:
Sep 30, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03968419

View Complete Trial Details & Eligibility at ClinicalTrials.gov